Haleos Labs Limited
Haleos Labs Limited Share Price Today: Live Updates & Key Insights
Get insights on Haleos Labs Limited’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Haleos Labs Limited Share Price Chart
Haleos Labs Limited Fundamentals
Traded Volume: 889
Market Cap(Cr): 414
Avg Traded Price 1359.80
1 Year return 16.29%
Upper Circuit 1,440.5
Lower Circuit 1,325.2
P/E TTM 22.00
P/B Ratio 62.00
Traded Value(Cr) 12.18
EPS TTM 61.846
Book value 61.846
Dividend Yield 1Y 0.11%
Haleos Labs Limited Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Haleos Labs Limited stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Haleos Labs Limited share price history, short-term movements, long-term trends, and overall investor sentiment
1W +1.21%
1M +14.43%
3M +19.26%
1Y +16.29%
YTD +15.93%
Haleos Labs Limited Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Haleos Labs Limited daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 3079.00
Day Before Yesterday 2131.00
1W Avg 3132.40
1M Avg 3412.15
3M Avg 1783.65
Haleos Labs Limited Technical Details
Haleos Labs Limited technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 1317
Support 2 1263
Support 3 1201
Pivot Point : 1379
Resistance 1 1432
Resistance 2 1494
Resistance 3 1547
Haleos Labs Limited Corporate Actions
Haleos Labs Limited corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Haleos Labs Limited’s capital allocation strategies.
All
Ex-Date 24-Sep-2025 Type D Description 1.50/share@15.00% Record Date 24-Sep-2025 Ratio 15.00
Ex-Date 23-Sep-2024 Type D Description 1.50/share@15.00% Record Date 23-Sep-2024 Ratio 15.00
Ex-Date 22-Sep-2023 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00
Ex-Date 22-Sep-2022 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00
Ex-Date 20-Sep-2021 Type D Description 1.50/share@15.00% Record Date 21-Sep-2021 Ratio 15.00
Ex-Date 19-Sep-2019 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00
Dividends
Announcement Date 24-Sep-2025 Ex Dividend Date 24-Sep-2025 Dividend(%) 15
Announcement Date 23-Sep-2024 Ex Dividend Date 23-Sep-2024 Dividend(%) 15
Announcement Date 22-Sep-2023 Ex Dividend Date 22-Sep-2023 Dividend(%) 15
Announcement Date 22-Sep-2022 Ex Dividend Date 22-Sep-2022 Dividend(%) 15
Announcement Date 20-Sep-2021 Ex Dividend Date 20-Sep-2021 Dividend(%) 15
Announcement Date 19-Sep-2019 Ex Dividend Date 19-Sep-2019 Dividend(%) 15
Bonus
No Bonus has been declared by HALEOSLABS
Splits
No Split has been declared by HALEOSLABS
Others
Rights No Rights has been declared by HALEOSLABS
Haleos Labs Limited Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Haleos Labs Limited with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Haleos Labs Limited's relative performance and valuation against major competitors.
Stock Name Kerala Ayurveda Ltd ₹365.25 (+0.58%) M. Cap (Cr) 4.41 1 Yr Return (%) +18.30% P/E (TTM) -19.14 PB Ratio 10.71
Stock Name Amanta Healthcare Ltd ₹108.00 (+1.99%) M. Cap (Cr) 4.19 1 Yr Return (%) NaN% P/E (TTM) 31.48 PB Ratio 3.94
Stock Name Nectar Lifescience Ltd ₹18.50 (+6.20%) M. Cap (Cr) 4.15 1 Yr Return (%) -45.91% P/E (TTM) -1.15 PB Ratio 0.43
Stock Name Haleos Labs Limited ₹1369.90 (-1.49%) M. Cap (Cr) 4.14 1 Yr Return (%) +16.29% P/E (TTM) 22.15 PB Ratio 2.21
Stock Name Everest Organics Ltd ₹410.85 (-2.87%) M. Cap (Cr) 3.99 1 Yr Return (%) +188.92% P/E (TTM) 60.70 PB Ratio 9.51
Stock Name Valiant Laboratories Ltd ₹67.11 (-0.94%) M. Cap (Cr) 3.64 1 Yr Return (%) -37.39% P/E (TTM) 71.90 PB Ratio 1.15
Stock Name Trident Lifeline Ltd ₹311.50 (+3.44%) M. Cap (Cr) 3.63 1 Yr Return (%) +6.77% P/E (TTM) 34.69 PB Ratio 6.31
Haleos Labs Limited Cash Flow
Cash flow data provides a view of how money is generated and spent by Haleos Labs Limited, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 28.03 Mar 2024 14.75 Mar 2023 4.58 Mar 2022 -14.66 Mar 2021 21.62
PARTICULARS Investing Activities Mar 2025 -13.77 Mar 2024 -13.75 Mar 2023 -27.96 Mar 2022 -7.49 Mar 2021 -5.94
PARTICULARS Financing Activities Mar 2025 -14.20 Mar 2024 -0.82 Mar 2023 22.59 Mar 2022 14.63 Mar 2021 -7.87
PARTICULARS Net Cash Flow Mar 2025 0.07 Mar 2024 0.18 Mar 2023 -0.80 Mar 2022 -7.52 Mar 2021 7.81
Haleos Labs Limited Shareholding Pattern
This shows the ownership breakdown of Haleos Labs Limited, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 71.41%
Public 28.57%
Other Institutions 0.03%
FII N/A%
Mutual Funds N/A%
About Haleos Labs Limited
SMS Lifesciences India Limited was incorporated originally as Potluri Real Estate Private Limited on May 31, 2006. The Company's name was changed to Potluri Packaging Industries Private Limited on 6 November, 2013 and again changed to SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector. The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016.The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates. The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments. SMS Group was given the export house status in the year 1997-98.Having three multi product facilities in operation and a research centre, the Company executed contract manufacturing and research assignment for global customer base. The Scheme of Arrangement between SMS Pharmaceuticals Limited with the Company was implemented in 2016-17. Pursuant to the Scheme, the Semi Regulated facilities i.e Unit No. I, IV and V along with premises situated at Industrial Estate, Sanathnagar, Hyderabad; Industrial Development Area, Jeedimetla, Hyderabad; Premises bearing Flat No.417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad; vacant land admeasuring Ac 19.00 cents situated at Pharma City, Parawada, Visakhapatnam and Investments relating to Semi Regulated Units of SMS Pharmaceuticals Limited got demerged into the Company and the said Scheme of Demerger was given effect on May 17, 2017. The Company allotted 30,23,287 Equity Shares of Rs. 10 each to the shareholders of SMS Pharmaceuticals Limited on 27 June, 2017 in pursuance of Demerger Scheme.The Company made Mahi Drugs Private Limited as a wholly owned subsidiary of the Company in 2017-18. by acquiring 9,00,000 Equity Shares effective on 17th September, 2018. Similarly, the Company diluted its 10% stake in Mahi Drugs Private Limited during the period 2021-22 and it ceased to be a wholly-owned subsidiary of the Company w.e.f. 7th February, 2022.Company completed two regulatory inspections by the US Food and Drug Administration (USFDA). Company's Unit 1 at Kazipally, Hyderabad underwent USFDA inspection in May, 2025, resulting in a successful outcome with a Voluntary Action Indicated (VAI) status. Additionally, the Company's subsidiary, Mahi Drugs also successfully completed its USFDA inspection in February, 2025 of its manufacturing facility located in Vizag, Andhra Pradesh. Company expanded the new API production line, which is expected to become operational in the latter half of the year 2025-26.
Managing Director
T V V S N Murthy
Registered office Plot No 19-III Road No 71, Opp Bharatiya Vidya Bhavan PSc, Hyderabad, Telangana, 500096
FAX :91-040-6628-8888
Background
Incorporation Year 2006
Face Value ₹10.00
Market Lot 1
FAQs on Haleos Labs Limited
How to buy Haleos Labs Limited shares on NSE?
To buy Haleos Labs Limited shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Haleos Labs Limited share price today?
The Haleos Labs Limited share price on NSE is ₹1369.90 today.
What is the market cap of Haleos Labs Limited on NSE?
The company has a market capitalization of ₹414.16.
What is the PE & PB ratio of Haleos Labs Limited?
PE is 22 and PB is 62.
What is the 52 Week High and Low of Haleos Labs Limited shares?
Haleos Labs Limited stock price high: ₹1680 Haleos Labs Limited stock price low: ₹959.80.